Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 381

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 381
---
 shareholders. AI Integration and Future Development MultiplAI’s AI technology primarily utilizes classic machine learning algorithms. However, we have adopted a broader and more ambitious strategy, focusing on the development of Generative AI foundation models. These models will be trained by omni -modaldata collected from our comprehensive services suite. The data obtained through the commercial agreement which we expect to enter into with MultiplAI will further enhance these foundation models. To support our AI strategy, we plan to build our in -houseexpertise to develop AI and genomic solutions. This self -developmentapproach involves bringing together a specialized team of AI and genomics experts, utilizing more advanced and user -friendlytechnology to enhance the accuracy, precision, and overall performance of its genomic services while significantly reducing costs. Our strategic vision includes the creation of AI Agents, aimed at generating additional revenue streams and providing value to pharmaceutical companies, medical institutions, and clinical labs. We plan to derive these AI Agents from pre -trainedfoundation models, designed to support diverse health management scenarios. Despite the Notice of Termination and MultiplAI SPA Termination Agreement relating to MultiplAI, we remain steadfastly committed to its long -termvision of innovating AI -drivenhealthcare solutions. The development and advancement of these technologies continue unimpacted, underscoring our unwavering dedication to their strategic goals. Rewell Improving the precision of Health Indicators, Health Reports and Actionable Habit Plans In 2023, we released a total of 18 additional indicators for Rewell, expanding our DNA and microbiome result offering to customers, based on feedback received. Currently, we are advancing a series of strategic initiatives to elevate the functionality and impact of our Rewell platform. Key enhancements include refining the user interface and the narrative quality of our health reports, with a particular focus on enriching the ancestral section for greater user engagement. We are also finalizing the local validation of polygenic risk scores for cardiovascular diseases and Type 2 Diabetes, anticipating their integration into our health assessments for more personalized health insights, which we expect to produce synergies with Clinical Diagnostic’s R&D pipeline. A customer feedback channel will also be implemented, to capture user responses on the relevance, validation, and clarity of the health indicators presented in our reports. This is part of our broader strategy to improve the interpretability of the Rewell habit plans, ensuring that they not only inform but also inspire actionable health choices. Additionally, we plan to introduce new health indicators that align with customer needs and market trends. 197 In addition